SG11201704386VA - Anticancer compositions - Google Patents
Anticancer compositionsInfo
- Publication number
- SG11201704386VA SG11201704386VA SG11201704386VA SG11201704386VA SG11201704386VA SG 11201704386V A SG11201704386V A SG 11201704386VA SG 11201704386V A SG11201704386V A SG 11201704386VA SG 11201704386V A SG11201704386V A SG 11201704386VA SG 11201704386V A SG11201704386V A SG 11201704386VA
- Authority
- SG
- Singapore
- Prior art keywords
- anticancer compositions
- anticancer
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196605 | 2014-12-05 | ||
| PCT/US2015/063671 WO2016090105A1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704386VA true SG11201704386VA (en) | 2017-06-29 |
Family
ID=52006907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704386VA SG11201704386VA (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US10285948B2 (en) |
| EP (2) | EP3226843B1 (en) |
| JP (1) | JP6830892B2 (en) |
| KR (1) | KR102387089B1 (en) |
| CN (1) | CN106999432A (en) |
| AR (1) | AR102925A1 (en) |
| AU (1) | AU2015358497B2 (en) |
| CA (1) | CA2969675C (en) |
| CL (1) | CL2017001373A1 (en) |
| CO (1) | CO2017005574A2 (en) |
| CR (1) | CR20170218A (en) |
| CY (1) | CY1124504T1 (en) |
| DK (1) | DK3226843T3 (en) |
| EA (1) | EA201791251A1 (en) |
| ES (1) | ES2883187T3 (en) |
| HR (1) | HRP20211140T1 (en) |
| HU (1) | HUE054935T2 (en) |
| IL (1) | IL252325A0 (en) |
| LT (1) | LT3226843T (en) |
| MA (1) | MA41111B1 (en) |
| MD (1) | MD3226843T2 (en) |
| MX (1) | MX2017007206A (en) |
| MY (1) | MY192931A (en) |
| NI (1) | NI201700068A (en) |
| PH (1) | PH12017500979A1 (en) |
| PL (1) | PL3226843T3 (en) |
| PT (1) | PT3226843T (en) |
| RS (1) | RS62421B1 (en) |
| SG (1) | SG11201704386VA (en) |
| SI (1) | SI3226843T1 (en) |
| TW (1) | TWI709403B (en) |
| UA (1) | UA123538C2 (en) |
| WO (1) | WO2016090105A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ745682A (en) | 2012-09-26 | 2019-09-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| MD3226843T2 (en) | 2014-12-05 | 2021-10-31 | Aragon Pharmaceuticals Inc | Anticancer compositions |
| CN111479560A (en) | 2017-10-16 | 2020-07-31 | 阿拉贡药品公司 | Antiandrogen for treating non-metastatic castration-resistant prostate cancer |
| WO2020144649A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Pharmaceutical composition comprising enzalutamide dispersed in apple sauce |
| CN113711316A (en) | 2019-01-30 | 2021-11-26 | 詹森药业有限公司 | Methods for treating prostate cancer based on molecular subtypes |
| CN113365623A (en) | 2019-01-30 | 2021-09-07 | 阿拉贡药品公司 | Antiandrogen for treating metastatic castration sensitive prostate cancer |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| US11723898B2 (en) | 2019-11-04 | 2023-08-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| TW202228794A (en) | 2020-09-04 | 2022-08-01 | 美商艾瑞岡醫藥公司 | Methods for treating prostate cancer |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| WO2024189186A1 (en) | 2023-03-16 | 2024-09-19 | Bayer Consumer Care Ag | Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0633893T3 (en) | 1992-03-31 | 2000-04-17 | Btg Int Ltd | 17-Substituted steroids useful in cancer treatment |
| PT901786E (en) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Solid pharmaceutical dispersions with enhanced bioavailability |
| WO2001060410A1 (en) | 2000-02-21 | 2001-08-23 | Takeda Chemical Industries, Ltd. | Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same |
| HUP0302847A3 (en) | 2001-02-27 | 2005-05-30 | Astrazeneca Ab | Pharmaceutical formulation comprising bicalutamide |
| ATE324886T1 (en) | 2001-04-02 | 2006-06-15 | Astrazeneca Ab | SOLID MEDICINAL COMPOSITION CONTAINING 4'-CYANO-TRIFLUORO-3-(4-FLUOROPHENYLSULPHONYL) -2-HYDROXY- 2-METHYLPROPIONO- M TOLUIDIDE AND PVP |
| OA12624A (en) | 2001-06-22 | 2006-06-12 | Pfizer Prod Inc | Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers. |
| SE0103424D0 (en) | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
| EP1469830A2 (en) | 2002-02-01 | 2004-10-27 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| JPWO2003077827A1 (en) | 2002-03-19 | 2005-07-14 | 日本新薬株式会社 | Method for producing pharmaceutical solid dispersion |
| CN1878539B (en) | 2003-12-15 | 2010-06-23 | 科学与工业研究委员会 | Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer |
| PT3412290T (en) | 2006-03-27 | 2021-04-19 | Univ California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| SG173178A1 (en) * | 2009-04-03 | 2011-09-29 | Hoffmann La Roche | Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
| EA028869B1 (en) | 2010-02-16 | 2018-01-31 | Арагон Фармасьютикалс, Инк. | Androgen receptor modulators and use thereof |
| CN102525876B (en) * | 2010-12-15 | 2014-03-12 | 西安力邦医药科技有限责任公司 | Aspirin solid dispersion, as well as preparation method, pharmaceutical composition and use thereof |
| AU2012271403C1 (en) | 2011-06-15 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| US20150037407A1 (en) | 2012-03-21 | 2015-02-05 | Emphascience, Inc. | Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy |
| WO2013152342A1 (en) * | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| PE20150631A1 (en) | 2012-06-07 | 2015-05-11 | Aragon Pharmaceuticals Inc | CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| MX2015002430A (en) | 2012-08-24 | 2015-06-22 | Dow Global Technologies Llc | Novel hydroxyalkyl methyl cellulose acetate succinates. |
| DK3725778T3 (en) | 2012-09-11 | 2021-09-20 | Medivation Prostate Therapeutics Llc | ENZALUTAMIDE FORMULATIONS |
| US9977033B2 (en) | 2012-09-11 | 2018-05-22 | The Board Of Regents Of The University Of Texas System | Methods for assessing cancer recurrence |
| NZ745682A (en) * | 2012-09-26 | 2019-09-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| JOP20200097A1 (en) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | Androgen receptor modulator and uses thereof |
| NZ708272A (en) | 2013-01-22 | 2020-07-31 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
| KR20160023641A (en) | 2013-03-15 | 2016-03-03 | 아이슈티카 인코포레이티드 | Abiraterone acetate formulation |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| KR20160058774A (en) | 2013-08-12 | 2016-05-25 | 토카이 파마슈티컬, 아이엔씨. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| WO2015116696A1 (en) * | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| CN106102716A (en) | 2014-02-05 | 2016-11-09 | 斯洛文尼亚莱柯制药股份有限公司 | The solid composite medicament of androgen receptor antagonists |
| BR112016018288A2 (en) | 2014-02-06 | 2017-10-10 | Hoffmann La Roche | interleukin 2 fusion proteins and their use |
| TWI718102B (en) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | Amorphous body of tetracyclic compound |
| MA41107A (en) | 2014-12-05 | 2017-10-10 | Aragon Pharmaceuticals Inc | ANTI-CANCER COMPOSITIONS |
| MD3226843T2 (en) | 2014-12-05 | 2021-10-31 | Aragon Pharmaceuticals Inc | Anticancer compositions |
| CA2969661C (en) | 2014-12-05 | 2023-04-25 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| AR108489A1 (en) * | 2016-06-03 | 2018-08-29 | Aragon Pharmaceuticals Inc | ANTHINEOPLASTIC COMPOSITIONS |
-
2015
- 2015-12-03 MD MDE20170154T patent/MD3226843T2/en unknown
- 2015-12-03 HU HUE15820351A patent/HUE054935T2/en unknown
- 2015-12-03 MY MYPI2017701986A patent/MY192931A/en unknown
- 2015-12-03 SI SI201531686T patent/SI3226843T1/en unknown
- 2015-12-03 KR KR1020177018243A patent/KR102387089B1/en active IP Right Grant
- 2015-12-03 MX MX2017007206A patent/MX2017007206A/en unknown
- 2015-12-03 CA CA2969675A patent/CA2969675C/en active Active
- 2015-12-03 CN CN201580066235.3A patent/CN106999432A/en active Pending
- 2015-12-03 WO PCT/US2015/063671 patent/WO2016090105A1/en active Application Filing
- 2015-12-03 SG SG11201704386VA patent/SG11201704386VA/en unknown
- 2015-12-03 JP JP2017529774A patent/JP6830892B2/en active Active
- 2015-12-03 TW TW104140459A patent/TWI709403B/en not_active IP Right Cessation
- 2015-12-03 DK DK15820351.3T patent/DK3226843T3/en active
- 2015-12-03 EP EP15820351.3A patent/EP3226843B1/en active Active
- 2015-12-03 LT LTEP15820351.3T patent/LT3226843T/en unknown
- 2015-12-03 US US15/533,229 patent/US10285948B2/en active Active
- 2015-12-03 UA UAA201707015A patent/UA123538C2/en unknown
- 2015-12-03 RS RS20211035A patent/RS62421B1/en unknown
- 2015-12-03 EP EP21175525.1A patent/EP3925598A1/en active Pending
- 2015-12-03 AU AU2015358497A patent/AU2015358497B2/en active Active
- 2015-12-03 CR CR20170218A patent/CR20170218A/en unknown
- 2015-12-03 PL PL15820351T patent/PL3226843T3/en unknown
- 2015-12-03 MA MA41111A patent/MA41111B1/en unknown
- 2015-12-03 PT PT158203513T patent/PT3226843T/en unknown
- 2015-12-03 EA EA201791251A patent/EA201791251A1/en unknown
- 2015-12-03 ES ES15820351T patent/ES2883187T3/en active Active
- 2015-12-04 AR ARP150103981A patent/AR102925A1/en unknown
-
2017
- 2017-05-16 IL IL252325A patent/IL252325A0/en unknown
- 2017-05-26 PH PH12017500979A patent/PH12017500979A1/en unknown
- 2017-05-29 CL CL2017001373A patent/CL2017001373A1/en unknown
- 2017-06-02 NI NI201700068A patent/NI201700068A/en unknown
- 2017-06-05 CO CONC2017/0005574A patent/CO2017005574A2/en unknown
-
2019
- 2019-03-19 US US16/357,821 patent/US11224575B2/en active Active
-
2021
- 2021-03-15 US US17/201,811 patent/US11911511B2/en active Active
- 2021-07-19 HR HRP20211140TT patent/HRP20211140T1/en unknown
- 2021-08-13 CY CY20211100730T patent/CY1124504T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279833A (en) | Anticancer compositions | |
| IL252324A0 (en) | Anticancer compositions | |
| IL252325A0 (en) | Anticancer compositions | |
| GB201419257D0 (en) | Pharmaceutical compositions | |
| GB201618482D0 (en) | Pharmaceutical compositions | |
| IL249553A0 (en) | Pharmaceutical compositions | |
| IL263157A (en) | Anticancer compositions | |
| GB201703061D0 (en) | Polyphenol compositions | |
| IL251479A0 (en) | Compositions | |
| GB201408167D0 (en) | Compositions | |
| IL250817A0 (en) | Pharmaceutical compositions | |
| GB201420306D0 (en) | Compositions | |
| GB201419849D0 (en) | Compositions | |
| HUE036695T2 (en) | Ubidecarenone composition | |
| GB201415634D0 (en) | Novel compositions | |
| GB202009707D0 (en) | Anti-adherant botanical compositions | |
| GB201406863D0 (en) | Compositions comprising variegin | |
| SG2014014872A (en) | Pharmaceutical compositions | |
| GB201408432D0 (en) | Pharmaceutical compositions | |
| GB201401510D0 (en) | Composition |